Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
Emerging strategies to target RAS signaling in human cancer therapy
K Chen, Y Zhang, L Qian, P Wang - Journal of hematology & oncology, 2021 - Springer
Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
DR Camidge, RC Doebele, KM Kerr - Nature reviews Clinical oncology, 2019 - nature.com
The era of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC)
began when biomarker-based evidence of molecular pathway and/or oncogene addiction of …
began when biomarker-based evidence of molecular pathway and/or oncogene addiction of …
[HTML][HTML] Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer
H Borghaei, L Paz-Ares, L Horn… - … England Journal of …, 2015 - Mass Medical Soc
Background Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-
checkpoint–inhibitor antibody, disrupts PD-1–mediated signaling and may restore antitumor …
checkpoint–inhibitor antibody, disrupts PD-1–mediated signaling and may restore antitumor …
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Novello, F Barlesi, R Califano, T Cufer… - Annals of …, 2016 - annalsofoncology.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
D Planchard, S Popat, K Kerr, S Novello… - Annals of …, 2019 - annalsofoncology.org
1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
[HTML][HTML] Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed …
The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum …
Background Ramucirumab is a human IgG1 monoclonal antibody that targets the
extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with …
extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with …